Tehran University of Medical Sciences
Office of Vice-Chancellor for Global Strategies & International Affairs
International Human Capacity Development (IHCD)
Code : 9345-343641      Publish Date : Wednesday, December 24, 2014 Visit : 2392

Intl. Congress form | International Congress Report | International Congress Report For Faculty | the 9th International Respiratory Syncytial Virus Symposium

the 9th International Respiratory Syncytial Virus Symposium
The report of the 9th International Respiratory Syntactical Virus Symposium by Dr. Vahid Salimi
 
Application Code :
306-0214-0116
 
Created Date : Friday, December 5, 2014 19:17:39Update Date : Wednesday, December 10, 2014 11:26:41IP Address :194.225.57.14
Submit Date : Wednesday, December 10, 2014 11:27:29Email : vahidsalimii@gmail.com
Personal Information
Name : Vahid
Surname : Salimi
School/Research center : School of Public Health
If you choose other, please name your Research center :  
Possition : Assistant professor
Tel : +98-21-88962343
Information of Congress
Title of the Congress : the 9th International Respiratory Syncytial Virus Symposium
Title of your Abstract : Opioid Receptors Control Respiratory Syncytial Virus Replication
country : South Africa
From : Sunday, November 9, 2014
To : Thursday, November 13, 2014
Abstract(Please copy/paste the abstract send to the congress) : Background: Respiratory syncytial virus (RSV) is an important respiratory pathogen and the most common cause of bronchiolitis in infants and admissions to hospital worldwide. Opioids are frequently used during mechanical ventilation for severe viral infection in infancy. Opioid receptors have immunomodulatory properties, directly or indirectly leading to substantial changes in immune response during inflammation but nothing is known about their antiviral effects. We therefore aimed to investigate the role of opioid receptors in virus-induced airway inflammation.
Methods: Two single nucleotide polymorphisms in OPRM1 and OPRD1 were genotyped in 465 infants with severe respira¬tory syncytial virus infection and 930 control subjects. Subsequently, the mechanism by which opioid receptors affect clinical outcome in respiratory syncytial virus bronchiolitis was studied in animal model. Female BALB/c mice were infected with RSV and injected daily with nalmefene. The potential therapeutic effect of pharmaceutical opioids was studied using μ (DAMGO), κ (U50488), and δ (DPDPE) opioid receptor agonists 48 hrs after infection. Differential cell counts were performed on BAL. Viral titers were determined by real-time PCR. Cytokines and chemokines were determined using ELISA-kits. The histology slides were prepared from the same lungs used for BAL fluid.
Results: In our human study, the A118G single nucleotide polymorphism rs1799971 was associated with RSV disease severity. In mice, nalmefene treatment increased viral titers and was associated with more pro¬nounced weight loss. Increased viral replication was associated with increased levels of cytokines and chemokines in the bronchoalveolar lavage fluid, enhanced bronchoalveolar cellular influx, and exaggerat¬ed lung pathology. Pharmaceutical opioids did not affect viral replication. They did induce a decreased influx of neu¬trophils, but an increased influx of lymphocytes and monocytes into the bronchoalveolar lumen during respiratory syncytial virus infection.
Conclusions: Using a human study and an experimental model, we show that opioid receptor signaling has a potential beneficial role in the outcome of respiratory viral disease. We show that opioid receptor signaling is required to control respiratory syncytial virus replication and thereby to control disease severity. However, we also show that caution is required before using pharmaceutical opioids as anti-inflammatory or antiviral treatment of patients with viral respiratory infection.
Keywords of your Abstract : Respiratory Syncytial Virus ; RSV; Opioid Receptors; immunomodulatory; single nucleotide polymorphisms; SNP
Acceptance Letter : http://gsia.tums.ac.ir/images/UserFiles/13504/Forms/306/Acceptance Letter_1.pdf
The presentation : Oral
The Cover of Abstract book :
Published abstract in the abstract book with the related code :
Where has your abstract been indexed? : other
If you choose other, please name : http://www.rsv2014.co.za/
The Congress Reporting Form
How many volunteers were present at the Congress? : More than 600
Delegates from which countries presented in the congress? : Most of the countries all over the world including USA, UK, Netherlands, Japan, Italy, Spain, South Africa, Sweden, Canada, Germany, China, Iran, ...
Were the delegates of any other organizations present in the congress? : Yes
If yes, please write the names of the organizations in the box : WSPID, PATH
What were the responses to your talking points? Were specific questions or concerns raised? : The subject of my presentation impressed the RSV research groups and pediatricians because they used to apply morphine in the treatment of mechanically ventilated RSV patients but they did not know whether this might actually enhance airway inflammation and virus replication. The results of our research provided evidence that opioid receptor signaling is required to control respiratory syncytial virus replication and thereby to control disease severity. Most of the data have recently been published in Critical Care Medicine journal, but the importance of our data and the possible impact of these data on the ongoing projects, provoke me to present them in this congress which will provide me the chance of visiting celebrated experts from all over the world and sharing our experience with them in the field of RSV. There were lots of questions around my topic during the symposium. I also had a poster entitled '' Epidemiology of RSV in Iran'' and had a valuable discussion with WHO representative as well.
If you met staff members, please list their full names & positions. : Dr.Louis Bont from Netherlands
Dr.Shabir Madhi from UK
Dr.Frank Coenjaerts from Netherlands
Dr.Jose Melero from Spain
Dr.Barney Graham from USA
Dr.Peter Openshaw from UK
Dr.Martin Moore from USA
Dr.Uzma Bashir from Pakistan
Dr.Roberto Garofalo from USA
Dr.Ultan Power from UK
Dr.Teresa Johnson from USA
Please inform us if there are any follow up actions we need to talk with the members of the congress : Nothing..........................................................................................................................................................................................................................................................................................................................................................................................
Your experiences about the travel processes(Providing ticket, accommodation,...) : I had no specific problem but online money transferring is still difficult from our country.
Please give a briefing of your own observations and outcomes of the congress: : International Respiratory Syncytial Virus Symposium is the official conference of the RSV scientific community and continues the culture of exceptional meetings that was initiated in the mid 1990's and alternated between Europe and the USA for almost 2 decades. They moved this meeting for the first time to the African continent. The programs cover a broad range of topics, with many highlights including an opening presentation on the Global and regional morbidity and mortality estimates of RSV-associated acute lower respiratory infection in under-5 children, RSV vaccine and immunology research, RSV epidemiology in children, adults and immune-compromised patients; Innate and adaptive immunity, structure and function; advances in vaccine research and therapeutic, pathogenesis, molecular epidemiology, and advances in human metapneumovirus research. I talked with some key speaker in different sessions and achieved some opportunities to update my knowledge in different field of RSV as well as future collaboration.